CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
CAR-T 细胞治疗：传统癌症治疗策略的突破（综述）
英文原题：CAR‑T cell therapy: A breakthrough in traditional cancer treatment strategies (Review).
查看英文原题
CAR‑T cell therapy: A breakthrough in traditional cancer treatment strategies (Review).
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
嵌合抗原受体（CAR）T细胞疗法是一种创新的免疫细胞治疗方法，通过改造患者的T细胞，使其表面表达CAR蛋白，从而诱导其识别并破坏癌细胞。CAR-T 细胞疗法在治疗血液肿瘤方面已取得一定成功，但在实体瘤治疗中仍面临诸多挑战，如抗原选择、耐受性和安全性等问题。针对这些问题，研究不断改进CAR-T 细胞的设计，以追求更好的疗效和安全性。未来，CAR-T 细胞疗法有望成为重要的癌症治疗手段，并可能为个体化免疫治疗提供新的思路和策略。本综述全面概述了CAR-T 细胞疗法的原理、临床应用、治疗效果及面临的挑战。
展开英文摘要原文
Chimeric antigen receptor (CAR) T cell therapy is an innovative approach to immune cell therapy that works by modifying the T cells of a patient to express the CAR protein on their surface, and thus induce their recognition and destruction of cancer cells. CAR T cell therapy has shown some success in treating hematological tumors, but it still faces a number of challenges in the treatment of solid tumors, such as antigen selection, tolerability and safety.
In response to these issues, studies continue to improve the design of CAR T cells in pursuit of improved therapeutic efficacy and safety. In the future, CAR T cell therapy is expected to become an important cancer treatment, and may provide new ideas and strategies for individualized immunotherapy. The present review provides a comprehensive overview of the principles, clinical applications, therapeutic efficacy and challenges of CAR T cell therapy.
论文信息
- 作者
- Sun D、Shi X、Li S、Wang X、Yang X、Wan M
- 第一作者单位
- Department of General Surgery, Qianjiang Central Hospital, Qianjiang, Hubei 433100, P.R. China.China
- 通讯作者单位
- Department of Traditional Chinese Medicine, Qianjiang Central Hospital, Qianjiang, Hubei 433100, P.R. China.China
- 文献类型
- 综述
- 期刊
- Molecular medicine reports2024 Mar
- 原文标识
- PubMed 38275119 · DOI 10.3892/mmr.2024.13171
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →